---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000172"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T08:49:38.219820+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intelligent Bio Solutions expects sixth U.S. patent for fingerprint drug testing technology

## Summary
- Expected patent will protect lateral flow technology core to its drug screening system.
- Patent strengthens IP portfolio as company plans U.S. market entry in 2025.
- CEO Harry Simeonidis states protection is critical for scaling U.S. footprint.
- Recent FDA 510(k) submission supports non-invasive sweat-based testing approach.
- INBS provides non-invasive alternative to traditional drug screening methods.

## SEC filing metadata
- accession: 0001641172-25-000172
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000164117225000172/0001641172-25-000172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000164117225000172/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000172
- JSON: https://secwatch.observer/filing/0001641172-25-000172.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000172.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.